Vis enkel innførsel

dc.contributor.authorMadssen, Torfinn Støve
dc.contributor.authorCao, Maria Dung
dc.contributor.authorPladsen, Arne Valebjørg
dc.contributor.authorOttestad, Lars
dc.contributor.authorSahlberg, Kristine Kleivi
dc.contributor.authorBathen, Tone Frost
dc.contributor.authorGiskeødegård, Guro F.
dc.date.accessioned2019-12-19T06:58:16Z
dc.date.available2019-12-19T06:58:16Z
dc.date.created2019-12-04T15:03:18Z
dc.date.issued2019
dc.identifier.citationMetabolites. 2019, 9 (11)nb_NO
dc.identifier.issn2218-1989
dc.identifier.urihttp://hdl.handle.net/11250/2634059
dc.description.abstractBackground: Metabolomic characterization of tumours can potentially improve prediction of cancer prognosis and treatment response. Here, we describe efforts to validate previous metabolomic findings using a historical cohort of breast cancer patients and discuss challenges with using older biobanks collected with non-standardized sampling procedures. Methods: In total, 100 primary breast cancer samples were analysed by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS) and subsequently examined by histology. Metabolomic profiles were related to the presence of cancer tissue, hormone receptor status, T-stage, N-stage, and survival. RNA integrity number (RIN) and metabolomic profiles were compared with an ongoing breast cancer biobank. Results: The 100 samples had a median RIN of 4.3, while the ongoing biobank had a significantly higher median RIN of 6.3 (p = 5.86 × 10−7). A low RIN was associated with changes in choline-containing metabolites and creatine, and the samples in the older biobank showed metabolic differences previously associated with tissue degradation. The association between metabolomic profile and oestrogen receptor status was in accordance with previous findings, however, with a lower classification accuracy. Conclusions: Our findings highlight the importance of standardized biobanking procedures in breast cancer metabolomics studies.nb_NO
dc.language.isoengnb_NO
dc.publisherMDPInb_NO
dc.relation.urihttps://www.mdpi.com/2218-1989/9/11/278
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleHistorical Biobanks in Breast Cancer Metabolomics — Challenges and Opportunitiesnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.volume9nb_NO
dc.source.journalMetabolitesnb_NO
dc.source.issue11nb_NO
dc.identifier.doihttps://doi.org/10.3390/metabo9110278
dc.identifier.cristin1756711
dc.description.localcode© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-) license (http://creativecommons.org/licenses/by/4.0/).nb_NO
cristin.unitcode194,65,25,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal